PURPOSE: To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission. PATIENTS AND METHODS: Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery andplatinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo was administered as 1-mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient. The primary end point was RFS; secondary end points were OS and immunologic response. RESULTS: Characteristics of the 888 patients included: mean age, 56.3 years; Eastern Cooperative Oncology Group performance status, ≤ 1 in > 99% of patients; serous papillary subtype, 81.5%; stage III, 85.9%; and cancer antigen 125 ≤ 35 U/mL after third cycle, 80.9%. Mean exposure to study treatment (± standard deviation) was 449.7 ± 333.08 days. Hazard ratio (HR) of RFS for the treatment group using tumor size categorization (≤ 1 cm, > 1 cm) was 1.099 (95% CI, 0.919 to 1.315; P = .301). HR of OS using tumor size categorization (≤ 1 cm, > 1 cm) was 1.150 (95% CI, 0.872 to 1.518; P = .322). The most frequently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 212 patients (23.9%), respectively. By the final visit, median anti-anti-idiotypic antibody level was 493,000.0 ng/mL, indicating a robust response. CONCLUSION:Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response. Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS.
RCT Entities:
PURPOSE: To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission. PATIENTS AND METHODS: Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo was administered as 1-mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient. The primary end point was RFS; secondary end points were OS and immunologic response. RESULTS: Characteristics of the 888 patients included: mean age, 56.3 years; Eastern Cooperative Oncology Group performance status, ≤ 1 in > 99% of patients; serous papillary subtype, 81.5%; stage III, 85.9%; and cancer antigen 125 ≤ 35 U/mL after third cycle, 80.9%. Mean exposure to study treatment (± standard deviation) was 449.7 ± 333.08 days. Hazard ratio (HR) of RFS for the treatment group using tumor size categorization (≤ 1 cm, > 1 cm) was 1.099 (95% CI, 0.919 to 1.315; P = .301). HR of OS using tumor size categorization (≤ 1 cm, > 1 cm) was 1.150 (95% CI, 0.872 to 1.518; P = .322). The most frequently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 212 patients (23.9%), respectively. By the final visit, median anti-anti-idiotypic antibody level was 493,000.0 ng/mL, indicating a robust response. CONCLUSION:Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response. Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS.
Authors: J Pfisterer; A du Bois; J Sehouli; S Loibl; S Reinartz; A Reuss; U Canzler; A Belau; C Jackisch; R Kimmig; K Wollschlaeger; V Heilmann; F Hilpert Journal: Ann Oncol Date: 2006-10 Impact factor: 32.976
Authors: René H Verheijen; Leon F Massuger; Benedict B Benigno; Agamemnon A Epenetos; Alberto Lopes; John T Soper; Janica Markowska; Rostislav Vyzula; Tom Jobling; Gordon Stamp; Gregory Spiegel; Dennis Thurston; Theo Falke; Joanna Lambert; Michael V Seiden Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Jonathan Berek; Peyton Taylor; William McGuire; L Mary Smith; Birgit Schultes; Christopher F Nicodemus Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Mahesh A Varia; Frederick B Stehman; Brian N Bundy; Jo Ann Benda; Daniel L Clarke-Pearson; Ronald D Alvarez; Harry J Long Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: M O Nicoletto; S Tumolo; C Falci; M Donach; E Visonà; A Rosabian; O Nascimben; G P Cima; O Vinante; P Azzoni; M V Fiorentino Journal: Int J Med Sci Date: 2004-06-01 Impact factor: 3.738
Authors: Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel Journal: Curr Treat Options Oncol Date: 2015-01
Authors: Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller Journal: Front Oncol Date: 2015-08-17 Impact factor: 6.244